Peptide library / Digestive & weight / BPC-157
BPC-157
A 15 amino acid gut-protein fragment studied almost entirely in animals, with growing interest in compounding.
Full analysis available. BPC-157 is under FDA compounding review, and we cover it in depth with the committee vote and our Peptide Evidence Index. Read the full BPC-157 analysis →
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Gut lining protectionAnimals
- Tendon and muscle healingAnimals
- Knee pain reliefSmall human studies
How it is thought to work
BPC-157 is reported in animals to promote blood vessel growth and modulate inflammatory signaling, but its mechanism in people is not established.
What the evidence shows
Most evidence comes from rodent studies by a small number of laboratories. Human data consist of a few small reports and an early trial of safety. There are no large randomized trials.
Safety and unknowns
Long-term safety in people is unknown. The compound promotes blood vessel growth, which raises theoretical concerns in people with cancer.
Regulatory status
Not FDA-approved. See our full BPC-157 profile for the 2026 advisory committee review.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Cagrilintide
In clinical trialsAn investigational long-acting amylin analog from Novo Nordisk, tested alone and combined with semaglutide.
Dulaglutide
FDA-approvedA once-weekly GLP-1 receptor agonist used in type 2 diabetes with proven heart benefit.
Apraglutide
In clinical trialsAn investigational weekly GLP-2 analog for short bowel syndrome with intestinal failure.
General information, not medical advice. Do not buy or inject unregulated peptides.